| Literature DB >> 21951686 |
Erin E Sandford1, Megan Orr, Emma Balfanz, Nate Bowerman, Xianyao Li, Huaijun Zhou, Timothy J Johnson, Subhashinie Kariyawasam, Peng Liu, Lisa K Nolan, Susan J Lamont.
Abstract
BACKGROUND: Avian pathogenic Escherichia coli (APEC) is detrimental to poultry health and its zoonotic potential is a food safety concern. Regulation of antimicrobials in food-production animals has put greater focus on enhancing host resistance to bacterial infections through genetics. To better define effective mechanism of host resistance, global gene expression in the spleen of chickens, harvested at two times post-infection (PI) with APEC, was measured using microarray technology, in a design that will enable investigation of effects of vaccination, challenge, and pathology level.Entities:
Mesh:
Year: 2011 PMID: 21951686 PMCID: PMC3190404 DOI: 10.1186/1471-2164-12-469
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Parameterization of treatment groups
| Group | Parameterization |
|---|---|
| NV-NC-D1 | μ |
| NV-NC-D5 | μ + τ1 |
| NV-C-D1-M | μ + β |
| NV-C-D5-M | μ + β + λ |
| NV-C-D1-S | μ + β + γ |
| NV-C-D5-S | μ + β + λ + γ + θ |
| V-NC-D1 | μ + α |
| V-NC-D5 | μ + α + τ2 |
| V-C-D1 | μ + α + β + φ |
| V-C-D5 | μ + α + β + φ + τ3 |
Figure 1Experimental design. Flow chart of experimental design and 10 treatment groups showing how bird numbers within each replicate were placed into each of the 10 treatment groups.
Figure 2Total lesion score distribution. Comparison of the distribution of lesion scores of challenged birds taken on day 1 between birds that received the vaccine and birds that did not receive the vaccine for all 4 replicates on (a) day 1 and (b) day 5 (P < 0.001).
Figure 3Significantly differentially expressed genes for contrasts of interest. Number of significantly differentially expressed genes between (a) treatment and control groups, (b) day 1 and day 5 within treatment, and (c) mild and severe groups (q-value < 0.05).
Figure 4Direction of response. Directionality of significantly differentially expressed genes found in various contrasts with a minimum fold change of 1.5. For each contrast, up-regulated means there is greater expression in the first group, down-regulated means there is greater expression in the second group listed (q-value < 0.05).
Figure 5Heatmap comparison of day 1 and day 5. Visual representation of log2 fold change differences for all treatment groups between day 1 and day 5. Genes included were significant in at least one contrast presented (q-value < 0.05). Positive fold change indicates greater expression on day 5.
Figure 6Heatmap comparison of treatments and controls. Visual representation of log2 fold change differences between all treatment groups and day appropriate NV-NC control. Genes included were significant in at least one contrast presented (q-value < 0.05). Positive fold change indicates greater expression in treatment group.
Number of GO biological terms found in each contrast
| Contrast | DE Genes | Biological Terms |
|---|---|---|
| NV-C Mild Day 1 vs. NV-NC Control Day 1 | 29 | 2 |
| NV-C Severe Day 1 vs. NV-NC Control Day 1 | 1101 | 27 |
| NV-C Severe Day 5 vs. NV-NC Control Day 5 | 1723 | 73 |
| V-C Day 1 vs. NV-NC Control Day 1 | 182 | 27 |
| V-C Day 5 vs. NV-NC Control Day 5 | 137 | 1 |
| NV-C Severe Day 1 vs. NV-C Severe Day 5 | 248 | 4 |
| NV-C Severe Day 5 vs. NV-C Mild Day 5 | 799 | 63 |
Number of differentially expressed (DE) genes found between contrasts of interest and the number of biological terms found using those genes.
Quantitative PCR validation
| Gene | Contrast | qPCR | Microarray |
|---|---|---|---|
| AvBD 2 | NV-C Severe Day 5 vs. NV-C Mild Day 5 | -3.035* | -2.038** |
| NV-C Severe Day 1 vs. NV-NC Control Day 1 | 2.954** | 1.552** | |
| NV-C Severe Day 5 vs. NV-NC Control Day 5 | -3.206** | -1.863** | |
| NV-C Severe Day 1 vs. NV-C Severe Day 5 | 5.525** | 2.931** | |
| AvBD 6 | NV-C Severe Day 1 vs. NV-NC Control Day 1 | 2.592** | 1.719** |
| NV-C Severe Day 1 vs. NV-C Severe Day 5 | 4.726** | 2.194** | |
| AvBD 7 | NV-C Severe Day 5 vs. NV-C Mild Day 5 | -4.259 | -3.440** |
| NV-C Severe Day 1 vs. NV-NC Control Day 1 | 1.214 | 1.731** | |
| NV-C Severe Day 1 vs. NV-C Severe Day 5 | 4.446* | 3.346** | |
| IL1B | NV-C Mild Day 1 vs. NV-NC Control Day 1 | 0.567 | 3.826** |
| NV-C Severe Day 1 vs. NV-NC Control Day 1 | 1.290 | 1.836** | |
| NV-C Severe Day 5 vs. NV-NC Control Day 5 | 2.296 | 1.960** | |
| IL6 | NV-C Severe Day 5 vs. NV-C Mild Day 5 | 2.263 | 1.117** |
| NV-C Severe Day 1 vs. NV-NC Control Day 1 | 3.027* | 1.227** | |
| NV-C Severe Day 5 vs. NV-NC Control Day 5 | 2.611 | 1.138** | |
| IFNG | NV-C Severe Day 5 vs. NV-C Mild Day 5 | 2.399** | 1.154** |
| NV-C Severe Day 5 vs. NV-NC Control Day 5 | 2.427** | 2.000** | |
| TLR 2 | NV-C Severe Day 1 vs. NV-NC Control Day 1 | -0.070 | 1.140** |
| NV-C Severe Day 5 vs. NV-NC Control Day 5 | 0.699 | 0.984** | |
| TLR 4 | NV-C Severe Day 5 vs. NV-NC Control Day 5 | 1.396* | 1.336** |
| MD-2 | NV-C Severe Day 5 vs. NV-C Mild Day 5 | 0.028 | 5.311** |
| NV-C Severe Day 5 vs. NV-NC Control Day 5 | 0.034 | 1.230** | |
| IL1-R, type II | NV-C Severe Day 1 vs. NV-C Mild Day 1 | 1.574 ** | 1.263** |
| NV-C Severe Day 1 vs. NV-NC Control Day 1 | 1.241 | 2.676** | |
Log2 fold change between contrasts presented. + values indicate higher expression in the first group, - values indicate higher expression in the second group. ** P value < 0.05 in qPCR, q-value < 0.05 in microarray, * P value < 0.10 in qPCR